Literature DB >> 2405608

Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.

D W Muller1, E J Topol, R M Califf, K N Sigmon, L Gorman, B S George, D J Kereiakes, K L Lee, S G Ellis.   

Abstract

The relationship between preinfarction clinical status and short-term outcome was prospectively evaluated in 775 patients hospitalized with acute myocardial infarction after reperfusion therapy. It was anticipated that a history of angina preceding myocardial infarction by more than 7 days would be associated with more extensive underlying coronary artery disease and a more complicated in-hospital course. However, although this group did have a higher risk profile for coronary artery disease (hypertension 53.6% vs 37.2%; diabetes 22.5% vs 12.1%; hyperlipidemia 19.4% vs 9.8%; mean number of risk factors 2.2 vs 1.7, p = 0.0001), a higher incidence of multivessel disease (57.7% vs 39.6%, p less than 0.0001), worse baseline global left ventricular function (left ventricular ejection fraction 48.8% vs 51.3%, p = 0.03), and impaired function of the noninfarct zone (-0.05 vs +0.46 SD/chord, p = 0.002), the in-hospital course was less complicated than in the group without prior angina. Patients without antecedent angina had a higher rate of reocclusion of the infarct-related artery (13.6% vs 8.2%; p = 0.048). Although the difference did not reach statistical significance (7.2% vs 4.6%; p = 0.21), the in-hospital mortality rate was also higher in this group. These findings suggest that a history of prior angina is not necessarily associated with an unfavorable short-term prognosis after reperfusion therapy. This may be related to the greater prior use by this group of beta-adrenergic- and calcium channel-blocking agents (23.1% vs 8.5% and 20.7% vs 3.8%, respectively). It may also be related to the beneficial effects of collateral vessels, myocardial preconditioning, or differences in the native fibrinolytic system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405608     DOI: 10.1016/s0002-8703(05)80008-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

Review 1.  Apoptosis in myocardial ischaemia and infarction.

Authors:  P A J Krijnen; R Nijmeijer; C J L M Meijer; C A Visser; C E Hack; H W M Niessen
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

Review 2.  The role of myocardial ischaemic preconditioning during beating heart surgery: biological aspect and clinical outcome.

Authors:  Efstratios Apostolakis; Nikolaos G Baikoussis; Nikolaos A Papakonstantinou
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-15

Review 3.  Organ preconditioning: the past, current status, and related lung studies.

Authors:  Shi-ping Luh; Pan-chyr Yang
Journal:  J Zhejiang Univ Sci B       Date:  2006-05       Impact factor: 3.066

Review 4.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

Review 5.  Salvage of jeopardized myocardium by ischemic preconditioning: is the quest over?

Authors:  R Strasser; P Htun; W Schaper
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

6.  Stress proteins: a future role in cardioprotection?

Authors:  S D Morris; D M Yellon; M S Marber
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

7.  Ischaemic preconditioning.

Authors:  M Marber; D Walker; D Yellon
Journal:  BMJ       Date:  1994-01-01

Review 8.  Ischaemic preconditioning of myocardium: a new paradigm for clinical cardioprotection?

Authors:  G F Baxter; D M Yellon
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 9.  Preconditioning the human myocardium: recent advances and aspirations for the development of a new means of cardioprotection in clinical practice.

Authors:  D P Jenkins; S E Steare; D M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

10.  Preinfarction angina reduces infarct size in ST-elevation myocardial infarction treated with percutaneous coronary intervention.

Authors:  Ronald Reiter; Timothy D Henry; Jay H Traverse
Journal:  Circ Cardiovasc Interv       Date:  2013-01-22       Impact factor: 6.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.